탈세포화 바이오소재 시장 예측(-2034년) : 바이오소재 원료, 조직 유래, 탈세포화 방법, 바이오소재 형태, 매트릭스 조성, 가공 및 개질, 용도, 최종사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Decellularized Biomaterials Market is accounted for $3.6 billion in 2026 and is expected to reach $9.2 billion by 2034 growing at a CAGR of 12.4% during the forecast period. The decellularized biomaterials market is expanding as these biomaterials gain importance in regenerative medicine, tissue engineering, wound treatment, and other biomedical fields. Decellularization eliminates cells and associated components from biological tissues while maintaining the extracellular matrix framework required for effective cellular interaction and tissue repair. Rising interest in biocompatible scaffolds, progress in regenerative medicine research, and improvements in tissue-processing methods are contributing to market development. Materials obtained from human and animal tissues are being explored for skin regeneration, cardiovascular repair, orthopedic applications, and engineered organs. Increasing biotechnology investments, growing adoption of personalized healthcare, and ongoing advances in regenerative therapies are expected to strengthen market opportunities.

Market Dynamics:

Driver:

Increasing Prevalence of Chronic and Tissue-Damaging Conditions

A growing burden of chronic illnesses, traumatic injuries, severe burns, and tissue disorders is driving demand for innovative solutions that facilitate tissue reconstruction and healing. Damage to skin, bone, cardiovascular structures, and other tissues often requires advanced regenerative approaches, creating a favorable environment for decellularized biomaterials. Because these materials can preserve essential extracellular matrix structures and biological characteristics, they are increasingly examined as scaffolds for supporting tissue restoration. Population aging further increases the occurrence of degenerative diseases and complex medical interventions. The need for improved healing outcomes and functional recovery is therefore encouraging healthcare researchers and providers to explore decellularized biomaterial-based therapeutic solutions.

Restraint:

High Manufacturing and Processing Costs

Expensive manufacturing and processing requirements represent a significant limitation for the decellularized biomaterials market. Production often involves sophisticated equipment, specialized facilities, biological tissue collection, sterilization, preservation, and comprehensive quality assessment. Achieving effective cell removal without damaging the extracellular matrix requires precisely controlled processes, increasing operational and workforce costs. Expenses related to tissue procurement, storage, contamination prevention, and biomaterial characterization further raise overall production costs. Compared with some synthetic biomaterials, these products may therefore have higher manufacturing expenses, making widespread adoption more challenging. Cost considerations can particularly affect healthcare organizations and manufacturers operating within constrained budgets or developing healthcare markets.

Opportunity:

Strategic Collaborations and Expansion into Emerging Markets

Partnerships and expansion into developing healthcare markets can generate new growth avenues for the decellularized biomaterials industry. Collaboration between biotechnology firms, hospitals, universities, and biomaterial manufacturers can bring together capabilities in tissue processing, cellular science, product development, manufacturing, and clinical research. These partnerships can help accelerate biomaterial validation and support the transition from experimental research to commercial healthcare applications. Meanwhile, rising healthcare expenditure, improving clinical infrastructure, and increasing awareness of regenerative medicine in emerging economies can support future demand. Companies that develop regional collaborations, strengthen supply and distribution channels, and offer economically viable biomaterial solutions could capture opportunities across growing healthcare markets.

Threat:

Potential Clinical Safety and Long-Term Performance Concerns

Uncertainty regarding long-term safety and performance can threaten broader adoption of decellularized biomaterials. Although decellularization is intended to reduce immune reactions, residual cellular components, processing chemicals, or contaminants may create potential safety concerns if not adequately controlled. Differences in scaffold degradation, remodeling, mechanical stability, and integration with surrounding tissues may also influence long-term clinical outcomes. Some applications require extensive evidence to demonstrate durability and consistent therapeutic performance over extended periods. Unexpected complications or insufficient clinical evidence could delay regulatory approvals and reduce physician confidence. Consequently, companies may face increased costs and longer development timelines when establishing the safety and effectiveness of new biomaterial products.

Covid-19 Impact:

COVID-19 temporarily constrained the decellularized biomaterials market through interruptions in medical supply chains, tissue procurement, laboratory access, manufacturing activities, and biomedical research. Restrictions on movement, transportation delays, workforce limitations, and reduced research capacity affected the progress of biomaterial development and clinical investigations. Shortages and logistical challenges involving biological matrices and essential laboratory resources further complicated research and production activities. At the same time, the pandemic highlighted the importance of regenerative medicine, biomedical innovation, and resilient healthcare supply systems. Overall, COVID-19 caused near-term market challenges but also encouraged stronger research collaboration, supply-chain resilience, and future biomaterial innovation.

The Hydrogel-Based Materials segment is expected to be the largest during the forecast period

The Hydrogel-Based Materials segment is expected to account for the largest market share during the forecast period, Decellularized matrix-derived hydrogels provide a hydrated and biologically relevant three-dimensional environment that can preserve key extracellular matrix signals and structures. These characteristics can encourage cellular adhesion, growth, differentiation, and tissue reconstruction. Their ability to be delivered in injectable form provides flexibility for minimally invasive procedures and enables adaptation to complex or irregular tissue sites. Consequently, hydrogel-based decellularized materials are being explored extensively for regenerative therapies, wound repair, controlled delivery systems, and biofabrication. Their compatibility with bioprinting and cell-based approaches further expands their potential for specialized tissue engineering applications.

The Neurological segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Neurological segment is predicted to witness the highest growth rate, Increasing research into neural tissue engineering is creating greater interest in decellularized biomaterials for neurological applications. Their preserved extracellular matrix characteristics can provide supportive biological signals for neural cell adhesion, movement, growth, and tissue restoration. Researchers are exploring these materials for peripheral nerve repair, neural regeneration, and scaffold development for complex neurological applications. The ability of decellularized matrices to retain tissue-specific biochemical properties makes them promising platforms for biomimetic regeneration. Continued advances involving stem cells, hydrogel formulations, and biofabrication techniques could broaden their use in neurological medicine and accelerate development of innovative regenerative solutions for nerve and neural tissue repair.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by well-developed healthcare systems, substantial regenerative medicine research, and growing activity in tissue engineering and extracellular matrix-based technologies. The region has a strong presence of biomaterial manufacturers, tissue-processing organizations, specialized healthcare facilities, and academic research centers, which facilitates technological advancement and clinical adoption. Increasing application of decellularized scaffolds in wound treatment, tissue repair, orthopedic reconstruction, and cardiovascular procedures is also contributing to regional demand. Strong clinical capabilities, research infrastructure, and established commercialization pathways are expected to maintain North America's prominent position in the decellularized biomaterials market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, Rapid improvements in healthcare infrastructure, increasing healthcare investment, and growing emphasis on regenerative medicine are creating strong opportunities across the region. China, Japan, South Korea, and India are advancing research and development in tissue engineering, biomaterials, and regenerative therapies. Greater adoption of advanced solutions for tissue repair, wound management, orthopedic procedures, and cardiovascular applications is also encouraging market expansion. The development of regional biotechnology capabilities, combined with stronger partnerships among hospitals, research organizations, and biomaterial developers, is supporting innovation and commercialization. Consequently, Asia Pacific is positioned for rapid market growth.

Key players in the market

Some of the key players in Decellularized Biomaterials Market include Integra LifeSciences Corporation, LifeNet Health, MTF Biologics, Cook Biotech Inc., Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic plc, Aroa Biosurgery Limited, RTI Surgical Holdings, Inc., CorMatrix Cardiovascular, Inc., Tissue Regenix Group plc, Humacyte, Inc., AxoGen, Inc., Miromatrix Medical Inc., Kerecis, TELA Bio, Inc., Smith+Nephew plc and B. Braun Melsungen AG.

Key Developments:

In May 2026, Cook Medical and Purdue University announced a new five-year Master Sponsored Research and Collaboration Agreement. The partnership establishes a framework for joint research, testing, and development of innovative medical technologies, including advanced medical-device manufacturing and materials science.

In June 2026, LEPU Medical reported an international collaboration involving Bakoulev National Medical Research Center for Cardiovascular Surgery and Chinese cardiovascular experts during the first Russia implantation of its biodegradable occluders.

In March 2026, Terumo BCT entered into a collaboration with Taiwan Bio Therapeutics to transition regulatory T-cell manufacturing to the automated Quantum Flex platform. The work combines Taiwan Bio's Treg manufacturing expertise with Terumo's automated cell-expansion technology to establish a more scalable and standardized process for cell-based therapy development.

Biomaterial Sources Covered:

• Human-Derived Biomaterials
• Animal-Derived Biomaterials
• Plant-Derived Biomaterials

Tissue Sources Covered:

• Skin and Dermal Tissue
• Bone Tissue
• Cartilage Tissue
• Tendon and Ligament Tissue
• Skeletal Muscle Tissue
• Adipose Tissue
• Vascular Tissue
• Cardiac Tissue
• Nerve Tissue
• Liver Tissue
• Kidney Tissue
• Lung Tissue
• Pancreatic Tissue
• Intestinal Tissue
• Corneal and Ocular Tissue

Decellularization Methods Covered:

• Physical Methods
• Chemical Methods
• Enzymatic Methods
• Combined Methods

Biomaterial Forms Covered:

• Decellularized Tissue Sheets and Membranes
• Decellularized Tissue Powders
• Decellularized Hydrogels
• Decellularized Scaffolds
• Decellularized Tissue Particulates
• Decellularized Bioinks
• Decellularized ECM Solutions

Matrix Compositions Covered:

• Collagen-Rich Biomaterials
• Elastin-Rich Biomaterials
• Glycosaminoglycan-Rich Biomaterials
• Proteoglycan-Rich Biomaterials
• Fibronectin-Rich Biomaterials
• Laminin-Rich Biomaterials
• Multi-Component ECM Biomaterials

Processing and Modifications Covered:

• Native Decellularized Biomaterials
• Crosslinked Decellularized Biomaterials
• Functionalized Decellularized Biomaterials
• Mineralized Decellularized Biomaterials
• Composite Decellularized Biomaterials

Therapeutic Areas Covered:

• Orthopedic and Musculoskeletal
• Cardiovascular
• Dermatology and Wound Care
• Neurological
• Ophthalmic
• Hepatic
• Renal
• Pulmonary
• Gastrointestinal
• Dental and Oral

Route of Administrations Covered:

• Implantable
• Injectable
• Topical

Applications Covered:

• Tissue Engineering
• Wound Healing
• Organ Repair and Regeneration
• Cell Culture
• Drug Delivery
• Drug Discovery and Screening
• Disease Modeling
• 3D Bioprinting
• Implantable Medical Devices

End Users Covered:

• Hospitals and Clinics
• Academic and Research Institutions
• Biotechnology and Pharmaceutical Companies
• Medical Device Companies
• Contract Research Organizations
• Tissue Banks and Biobanks

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Decellularized Biomaterials Market, By Biomaterial Source

• 5.1 Human-Derived Biomaterials
• 5.2 Animal-Derived Biomaterials
• 5.3 Plant-Derived Biomaterials

6 Global Decellularized Biomaterials Market, By Tissue Source

• 6.1 Skin and Dermal Tissue
• 6.2 Bone Tissue
• 6.3 Cartilage Tissue
• 6.4 Tendon and Ligament Tissue
• 6.5 Skeletal Muscle Tissue
• 6.6 Adipose Tissue
• 6.7 Vascular Tissue
• 6.8 Cardiac Tissue
• 6.9 Nerve Tissue
• 6.10 Liver Tissue
• 6.11 Kidney Tissue
• 6.12 Lung Tissue
• 6.13 Pancreatic Tissue
• 6.14 Intestinal Tissue
• 6.15 Corneal and Ocular Tissue

7 Global Decellularized Biomaterials Market, By Decellularization Method

• 7.1 Physical Methods
• 7.2 Chemical Methods
• 7.3 Enzymatic Methods
• 7.4 Combined Methods

8 Global Decellularized Biomaterials Market, By Biomaterial Form

• 8.1 Decellularized Tissue Sheets and Membranes
• 8.2 Decellularized Tissue Powders
• 8.3 Decellularized Hydrogels
• 8.4 Decellularized Scaffolds
• 8.5 Decellularized Tissue Particulates
• 8.6 Decellularized Bioinks
• 8.7 Decellularized ECM Solutions

9 Global Decellularized Biomaterials Market, By Matrix Composition

• 9.1 Collagen-Rich Biomaterials
• 9.2 Elastin-Rich Biomaterials
• 9.3 Glycosaminoglycan-Rich Biomaterials
• 9.4 Proteoglycan-Rich Biomaterials
• 9.5 Fibronectin-Rich Biomaterials
• 9.6 Laminin-Rich Biomaterials
• 9.7 Multi-Component ECM Biomaterials

10 Global Decellularized Biomaterials Market, By Processing and Modification

• 10.1 Native Decellularized Biomaterials
• 10.2 Crosslinked Decellularized Biomaterials
• 10.3 Functionalized Decellularized Biomaterials
• 10.4 Mineralized Decellularized Biomaterials
• 10.5 Composite Decellularized Biomaterials

11 Global Decellularized Biomaterials Market, By Therapeutic Area

• 11.1 Orthopedic and Musculoskeletal
• 11.2 Cardiovascular
• 11.3 Dermatology and Wound Care
• 11.4 Neurological
• 11.5 Ophthalmic
• 11.6 Hepatic
• 11.7 Renal
• 11.8 Pulmonary
• 11.9 Gastrointestinal
• 11.10 Dental and Oral

12 Global Decellularized Biomaterials Market, By Route of Administration

• 12.1 Implantable
• 12.2 Injectable
• 12.3 Topical

13 Global Decellularized Biomaterials Market, By Application

• 13.1 Tissue Engineering
• 13.2 Wound Healing
• 13.3 Organ Repair and Regeneration
• 13.4 Cell Culture
• 13.5 Drug Delivery
• 13.6 Drug Discovery and Screening
• 13.7 Disease Modeling
• 13.8 3D Bioprinting
• 13.9 Implantable Medical Devices

14 Global Decellularized Biomaterials Market, By End User

• 14.1 Hospitals and Clinics
• 14.2 Academic and Research Institutions
• 14.3 Biotechnology and Pharmaceutical Companies
• 14.4 Medical Device Companies
• 14.5 Contract Research Organizations
• 14.6 Tissue Banks and Biobanks

15 Global Decellularized Biomaterials Market, By Geography

• 15.1 North America
  • 15.1.1 United States
  • 15.1.2 Canada
  • 15.1.3 Mexico
• 15.2 Europe
  • 15.2.1 United Kingdom
  • 15.2.2 Germany
  • 15.2.3 France
  • 15.2.4 Italy
  • 15.2.5 Spain
  • 15.2.6 Netherlands
  • 15.2.7 Belgium
  • 15.2.8 Sweden
  • 15.2.9 Switzerland
  • 15.2.10 Poland
  • 15.2.11 Rest of Europe
• 15.3 Asia Pacific
  • 15.3.1 China
  • 15.3.2 Japan
  • 15.3.3 India
  • 15.3.4 South Korea
  • 15.3.5 Australia
  • 15.3.6 Indonesia
  • 15.3.7 Thailand
  • 15.3.8 Malaysia
  • 15.3.9 Singapore
  • 15.3.10 Vietnam
  • 15.3.11 Rest of Asia Pacific
• 15.4 South America
  • 15.4.1 Brazil
  • 15.4.2 Argentina
  • 15.4.3 Colombia
  • 15.4.4 Chile
  • 15.4.5 Peru
  • 15.4.6 Rest of South America
• 15.5 Rest of the World (RoW)
  • 15.5.1 Middle East
    • 15.5.1.1 Saudi Arabia
    • 15.5.1.2 United Arab Emirates
    • 15.5.1.3 Qatar
    • 15.5.1.4 Israel
    • 15.5.1.5 Rest of Middle East
  • 15.5.2 Africa
    • 15.5.2.1 South Africa
    • 15.5.2.2 Egypt
    • 15.5.2.3 Morocco
    • 15.5.2.4 Rest of Africa

16 Strategic Market Intelligence

• 16.1 Industry Value Network and Supply Chain Assessment
• 16.2 White-Space and Opportunity Mapping
• 16.3 Product Evolution and Market Life Cycle Analysis
• 16.4 Channel, Distributor, and Go-to-Market Assessment

17 Industry Developments and Strategic Initiatives

• 17.1 Mergers and Acquisitions
• 17.2 Partnerships, Alliances, and Joint Ventures
• 17.3 New Product Launches and Certifications
• 17.4 Capacity Expansion and Investments
• 17.5 Other Strategic Initiatives

18 Company Profiles

• 18.1 Integra LifeSciences Corporation
• 18.2 LifeNet Health
• 18.3 MTF Biologics
• 18.4 Cook Biotech Inc.
• 18.5 Stryker Corporation
• 18.6 Zimmer Biomet Holdings, Inc.
• 18.7 Medtronic plc
• 18.8 Aroa Biosurgery Limited
• 18.9 RTI Surgical Holdings, Inc.
• 18.10 CorMatrix Cardiovascular, Inc.
• 18.11 Tissue Regenix Group plc
• 18.12 Humacyte, Inc.
• 18.13 AxoGen, Inc.
• 18.14 Miromatrix Medical Inc.
• 18.15 Kerecis
• 18.16 TELA Bio, Inc.
• 18.17 Smith+Nephew plc
• 18.18 B. Braun Melsungen AG